Somatostatin Receptor Imaging in Cardiac Sarcoidosis

Rigshospitalet

Status: Withdrawn

Conditions: Cardiac Sarcoidosis

Treatments: Drug: Cu-64 DOTATATE

Study type: Observational

Funder types: Other

Identifiers

NCT02812849

0001

Details and patient eligibility

About

The purpose of the trial is to determine the accuracy of Cu-64 labelled DOTATATE for diagnosing cardiac sarcoidosis using PET/CT or PET/MRI.

Sex: All

Ages: 18+ years old

Volunteers: No Healthy Volunteers

Inclusion criteria

Group A: Suspected cardiac sarcoidosis Group B: Known cardiac sarcoidosis, clinical follow-up Group C: Myocarditis or dilated cardiomyopathy (Non-cardiac sarcoidosis)

Exclusion criteria

Infection Pregnancy Severe claustrophobia Weight >140 kg

Trial design

0 participants in 3 patient groups

Suspected cardiac sarcoidosis

Description:

Cu-64 DOTATATE PET/CT or PET/MRI

Treatment:

Drug: Cu-64 DOTATATE

Known cardiac sarcoidosis

Description:

Cu-64 DOTATATE PET/CT or PET/MRI

Treatment:

Drug: Cu-64 DOTATATE

Other inflammatory cardiac disease

Description:

Cu-64 DOTATATE PET/CT or PET/MRI

Treatment:

Drug: Cu-64 DOTATATE